Cumberland Pharmaceuticals (CPIX) Short term Debt (2010 - 2024)

Cumberland Pharmaceuticals (CPIX) reported Short term Debt of $5.1 million for Q4 2024, down 14.84% sequentially from $6.0 million in Q3 2024.

Cumberland Pharmaceuticals (CPIX) Short term Debt (2010 - 2024) Analysis & Trends

Cumberland Pharmaceuticals (CPIX) has 4 years of Short term Debt data on file, last reported at $5.1 million in Q4 2024.

For the quarter ending Q4 2024, Short term Debt changed N/A year-over-year to $5.1 million; the trailing twelve-month figure through Dec 2024 stood at $5.1 million (changed N/A YoY), and the FY2024 full-year result was $5.1 million, changed N/A from the prior year.
Short term Debt declined to $5.1 million in Q4 2024, from $6.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $6.0 million in Q3 2024 to a low of $2.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Cumberland Pharmaceuticals	104.57 Mn	93.23 Mn	7.20 Mn

Download Data